Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report)'s stock price fell 4.4% on Tuesday . The company traded as low as $28.05 and last traded at $28.02. 92,307 shares traded hands during mid-day trading, a decline of 87% from the average session volume of 699,357 shares. The stock had previously closed at $29.30.
Analyst Ratings Changes
A number of research firms have weighed in on AGIO. StockNews.com lowered Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, February 14th. Scotiabank lifted their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a "sector outperform" rating in a research report on Monday, December 9th. HC Wainwright began coverage on shares of Agios Pharmaceuticals in a research report on Monday, February 24th. They set a "buy" rating and a $58.00 target price for the company. Cantor Fitzgerald reissued an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Finally, Royal Bank of Canada upped their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an "outperform" rating in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $56.57.
Check Out Our Latest Report on AGIO
Agios Pharmaceuticals Trading Down 4.5 %
The firm has a market cap of $1.52 billion, a price-to-earnings ratio of 2.34 and a beta of 0.90. The company has a fifty day moving average price of $32.73 and a 200-day moving average price of $40.40.
Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.
Insider Activity at Agios Pharmaceuticals
In related news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the transaction, the insider now owns 18,906 shares in the company, valued at $608,395.08. The trade was a 12.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.93% of the stock is owned by company insiders.
Hedge Funds Weigh In On Agios Pharmaceuticals
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Venturi Wealth Management LLC acquired a new stake in shares of Agios Pharmaceuticals in the 4th quarter worth $33,000. GF Fund Management CO. LTD. purchased a new stake in shares of Agios Pharmaceuticals in the fourth quarter valued at about $39,000. Wingate Wealth Advisors Inc. acquired a new stake in Agios Pharmaceuticals during the fourth quarter worth about $53,000. Sterling Capital Management LLC increased its position in Agios Pharmaceuticals by 818.0% during the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock worth $59,000 after purchasing an additional 1,587 shares during the last quarter. Finally, KBC Group NV raised its stake in Agios Pharmaceuticals by 30.5% during the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock worth $86,000 after purchasing an additional 611 shares during the period.
About Agios Pharmaceuticals
(
Get Free Report)
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
See Also
Before you consider Agios Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.
While Agios Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
